Back to search
Advanced Non-Hematologic Malignancies
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced Non-Hematologic Malignancies trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced Non-Hematologic Malignancies trials you may qualify forA study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philade…
This will be a phase 1, open-label, dose-escalation and expansion, FIH trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of JBZ-001,…
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 ad…
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genom…
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted th…
The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called…
This phase II MATCH treatment trial identifies the effects of trametinib in patients with cancer having genetic changes called BRAF mutations and fusions. Trame…